Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TVGN

Tevogen Bio Holdings Inc

Mar 10 • 04:00PM ET

7.79

+0.04 0.52 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA CRSP GILD FATE EDIT ALLO IMTX ADAP PSTX BLUE

| Held by: VTI IWM VTWO VXF IWO IWC IWN VTWG RSSL VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-8.88	Insider Own	78.37%	Shs Outstand	3.95M	Perf Week	-37.10%
Market Cap	31.54M	Forward P/E	-	EPS next Y	-9.50	Insider Trans	0.00%	Shs Float	0.88M	Perf Month	-43.26%
Enterprise Value	46.83M	PEG	-	EPS next Q	-2.00	Inst Own	2.52%	Short Float	6.81%	Perf Quarter	-61.11%
Income	-31.26M	P/S	-	EPS this Y	0.00%	Inst Trans	-	Short Ratio	3.17	Perf Half Y	-82.28%
Sales	0.00M	P/B	-	EPS next Y	-26.67%	ROA	-702.43%	Short Interest	0.06M	Perf YTD	-52.94%
Book/sh	-4.21	P/C	30.33	EPS next 5Y	-20.12%	ROE	-	52W High	75.50 -89.68%	Perf Year	-85.30%
Cash/sh	0.26	P/FCF	-	EPS past 3/5Y	-388.75% -	ROIC	-	52W Low	6.22 25.29%	Perf 3Y	-98.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	30.15% 13.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-234.22%	Oper. Margin	-	ATR (14)	1.66	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	24.43	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.31	EPS Q/Q	13.88%	SMA20	-35.97%	Beta	-0.64	Target Price	100.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-47.21%	Rel Volume	1.83	Prev Close	7.75
Employees	18	LT Debt/Eq	-	Earnings	Feb 25	SMA200	-78.11%	Avg Volume	18.89K	Price	7.79
IPO	Jan 05, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	34,538	Change	0.52%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-26	Downgrade	D. Boral Capital	Buy → Hold
Mar-04-25	Initiated	D. Boral Capital	Buy	$10

Mar-09-26 07:45AM	Tevogen Names Leadership Team to Execute Diversified Growth Strategy (GlobeNewswire) +6.02%
Mar-06-26 03:40PM	Letter to Shareholders from CEO Dr. Ryan Saadi (GlobeNewswire) -5.74%
12:42PM	Tevogen Bio Explores Buyout To Boost Generics Platform (Benzinga)
Mar-05-26 02:50PM	Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical (GlobeNewswire) -16.70%
Mar-04-26 08:00AM	Tevogen Announces Reverse Stock Split (GlobeNewswire) -24.83%
02:20PM	Loading…
Feb-27-26 02:20PM	Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization (GlobeNewswire) -8.71%
Feb-26-26 04:22PM	UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus (GlobeNewswire)
09:20AM	Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus (GlobeNewswire)
Jan-30-26 03:00PM	Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders (GlobeNewswire)
Jan-29-26 02:45PM	Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue (GlobeNewswire) -5.90%
Jan-12-26 09:00AM	Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025 (GlobeNewswire) -16.45%
Dec-22-25 12:40PM	Tevogen CEO Donates Shares to Support Education for Underprivileged Children (GlobeNewswire)
Dec-19-25 11:10AM	Tevogen CEO Donates Personal Shares to Support Local Fire Department (GlobeNewswire)
Dec-11-25 03:15PM	Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock (GlobeNewswire)
Dec-09-25 02:20PM	Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine (GlobeNewswire)
02:50PM	Loading…
Dec-08-25 02:50PM	Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook (GlobeNewswire) +8.81%
Nov-14-25 02:32PM	Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q (GlobeNewswire) -6.12%
Nov-05-25 03:20PM	Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID (GlobeNewswire) -5.42%
Nov-03-25 02:45PM	Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn (GlobeNewswire) -6.41%
Oct-29-25 12:35PM	Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress (GlobeNewswire)
Oct-15-25 03:50PM	Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest (GlobeNewswire) +7.32%
Sep-25-25 08:30AM	Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion (GlobeNewswire)
Sep-24-25 08:35AM	Tevogen highlights potential role of TVGN 489 on impact of Long COVID (TipRanks)
Sep-23-25 08:30AM	Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID (GlobeNewswire)
Sep-19-25 03:40PM	Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans (GlobeNewswire) -7.68%
Sep-10-25 11:59AM	Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston (GlobeNewswire)
Sep-09-25 03:15PM	Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection (GlobeNewswire)
Sep-08-25 09:27AM	Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform (GlobeNewswire)
Sep-04-25 03:48PM	Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas (GlobeNewswire)
Sep-03-25 04:15PM	Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 (GlobeNewswire)
03:20PM	Loading…
Aug-27-25 03:20PM	Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure (GlobeNewswire)
Aug-26-25 02:50PM	Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity (GlobeNewswire)
Aug-25-25 03:10PM	Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions (GlobeNewswire)
Aug-22-25 03:25PM	Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma (GlobeNewswire)
Aug-19-25 03:40PM	REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts (GlobeNewswire)
12:10PM	Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum (GlobeNewswire)
Aug-18-25 05:50PM	Tevogen CEO Donates Personal Shares to Support Local Law Enforcement (GlobeNewswire)
05:15PM	Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery (GlobeNewswire)
Aug-14-25 03:55PM	Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected (GlobeNewswire)
Aug-13-25 03:53PM	Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology (GlobeNewswire)
Aug-12-25 11:09AM	Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction (PR Newswire)
Aug-11-25 03:45PM	Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion (GlobeNewswire) +8.83%
01:24PM	REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion (GlobeNewswire)
11:58AM	Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow (GlobeNewswire)
09:28AM	REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders (GlobeNewswire)
Aug-08-25 11:37AM	REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions (GlobeNewswire)
Aug-07-25 09:00AM	Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy (GlobeNewswire) -8.75%
Aug-06-25 03:59PM	Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions (GlobeNewswire)
Aug-05-25 02:32PM	Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology (GlobeNewswire)
Aug-01-25 03:57PM	Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders (GlobeNewswire)
03:30PM	Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion (GlobeNewswire)
Jul-30-25 12:41PM	Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision (GlobeNewswire)
Jul-28-25 11:52AM	Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare (GlobeNewswire)
Jul-18-25 12:36PM	Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides (GlobeNewswire)
Jul-17-25 09:15AM	Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility (GlobeNewswire)
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire)
11:57AM	Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch (GlobeNewswire)
Jul-14-25 09:30AM	Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs (GlobeNewswire) +5.88%
Jul-10-25 03:13PM	Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation (GlobeNewswire)
Jun-30-25 02:28PM	Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters (GlobeNewswire)
09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
Jun-18-25 08:30AM	Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery (GlobeNewswire)
Jun-10-25 09:15AM	Tevogen expands headquarters in Warren, New Jersey (TipRanks) +12.73%
Jun-09-25 09:00AM	Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives (GlobeNewswire) -23.08%
May-30-25 11:01AM	Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships (GlobeNewswire)
May-25-25 06:19PM	Tevogen Peports Plans to Increase the Target Population for TVGN 489 (Insider Monkey)
May-23-25 03:49PM	Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow (GlobeNewswire) +6.50%
May-22-25 01:21PM	Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting (GlobeNewswire)
May-12-25 08:00AM	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation (GlobeNewswire) +9.17%
May-05-25 12:35PM	AI Healthcare Boom Gains Speed as Regulators and Innovators Align (PR Newswire)
May-02-25 03:45PM	Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest (GlobeNewswire)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.01%
Apr-30-25 03:49PM	CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment (GlobeNewswire)
Apr-29-25 04:50PM	Tevogen sees launch year oncology business revenue $1B (TipRanks) +7.74%
01:48PM	Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts (GlobeNewswire)
08:00AM	Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald (GlobeNewswire)
Apr-28-25 04:36PM	Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion (GlobeNewswire) -5.52%
Apr-25-25 02:33PM	Tevogen Bio Announces 2025 Annual Meeting (GlobeNewswire)
Apr-17-25 02:54PM	Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility (GlobeNewswire)
Apr-16-25 08:58AM	WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market (PR Newswire)
Apr-15-25 02:03PM	Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction (GlobeNewswire)
Apr-14-25 01:53PM	Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald (GlobeNewswire)
Apr-11-25 04:00PM	Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints (Seeking Alpha) +8.00%
Apr-09-25 02:45PM	Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States (GlobeNewswire) +16.67%
Apr-08-25 05:53PM	Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs (GlobeNewswire) -6.80%
Apr-07-25 03:58PM	Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission (GlobeNewswire)
Mar-26-25 03:12PM	Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast (GlobeNewswire)
Mar-25-25 01:11PM	Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan (GlobeNewswire)
Mar-10-25 12:40PM	Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO (GlobeNewswire) -7.02%
Mar-07-25 04:09PM	Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel (GlobeNewswire)
Mar-03-25 12:52PM	Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations (GlobeNewswire) -7.81%
Feb-28-25 01:17PM	Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy (GlobeNewswire)
Feb-21-25 03:28PM	Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned (GlobeNewswire) -8.71%
Feb-14-25 06:31PM	Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision (GlobeNewswire)
01:16PM	Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency (GlobeNewswire)
11:52AM	Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity (GlobeNewswire)
Feb-13-25 04:34PM	Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans (GlobeNewswire) -6.02%
Feb-10-25 05:30PM	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation (GlobeNewswire) +5.44%
Feb-07-25 02:56PM	Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell Technology's Potential as a Scalable Medical Countermeasure (GlobeNewswire)
Jan-29-25 02:33PM	Tevogen Bio Holdings Inc. (TVGN): Accelerating Precision Medicine with Microsoft AI Collaboration (Insider Monkey) -5.23%

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Desai Kirti	Officer	Feb 06 '26	Proposed Sale	0.31	330,000	103,224		Feb 06 03:09 PM
Desai Kirti	Officer	Dec 30 '25	Proposed Sale	0.40	15,500	6,149		Dec 30 10:12 AM
Saadi Ryan H.	Chief Executive Officer	Jun 09 '25	Sale	1.23	1,438,206	1,768,993	116,814,453	Jun 09 07:13 PM
Saadi Ryan H.	Officer	Jun 09 '25	Proposed Sale	1.10	1,438,206	1,582,027		Jun 09 05:45 PM
Flomenberg Neal	See Remarks	Mar 12 '25	Sale	1.09	232,968	253,935	3,595,608	Mar 14 09:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVGN

Tevogen Bio Holdings Inc

Upgrade your FINVIZ experience